Xencor | XNCR - Operating Profit


Xencor reported $-53.63M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
MacroGenics USD 18.64M 55.4M Sep/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Xencor USD -53.63M 6.11M Dec/2025